RPGLIFE: Investor Presentation on Unaudited Financial Results for Quarter Ended December 31, 2025
RPG Life Sciences released its investor presentation for the quarter ended December 31, 2025. Q3 FY26 revenue was ₹180 crore, up from ₹172.7 crore in Q3 FY25. EBITDA was ₹43.2 crore with a 24.0% margin. The company's long-term credit rating has been reaffirmed at A+ with a stable outlook, and the short-term rating at A1 by ICRA. The company aims to grow its immunosuppressant portfolio to over ₹200 crore.
The announcement provides information on the company's financial performance and strategic initiatives, which is relevant to investors and may influence their decisions.
The announcement primarily conveys financial results and business strategies, without explicitly positive or negative language.
RPG Life Sciences Limited has released a revised investor presentation regarding the unaudited financial results for the quarter ended December 31, 2025. This updates their previous communication on January 27, 2026, in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The presentation includes forward-looking statements based on certain assumptions, with the company clarifying that actual results may differ materially from these projections. The company operates in the Pharmaceutical segment.
RPG Life Sciences, founded in 1979, is part of RPG Enterprises. It operates in domestic and international markets with branded formulations, global generics, and synthetic APIs. The company has three manufacturing facilities and a presence in over 50 markets. Domestic Formulations contributed 70% to total sales of Q3 FY26. The company focuses on building mega brands, expanding its global presence, and sustainable operations, supported by a capital expenditure infusion of approximately ₹140 crore. They aim to grow the immunosuppressant portfolio to over ₹200 crore and Naprosyn to over ₹100 crore.
The company reported financial performance for Q3 FY26, with revenue from operations at ₹180 crore compared to ₹172.7 crore in Q3 FY25. EBITDA stood at ₹43.2 crore with a margin of 24.0%, while PBT (excluding exceptional items) was ₹37.5 crore with a margin of 20.9%. PAT (excluding exceptional items) was ₹27.9 crore with a margin of 15.5%. For 9M FY26, revenue from operations was ₹530.6 crore, EBITDA was ₹127.4 crore, PBT (excluding exceptional items) was ₹111.2 crore, and PAT (excluding exceptional items) was ₹82.6 crore. The company's long-term credit rating has been reaffirmed at A+ with a stable outlook, and the short-term rating at A1 by ICRA. Since FY22, ₹140 crore capex infused helped build modern plant with EU, TGA, PMDA, etc. approval.
What to do with a filing like this
RPG Life Sciences Limited filed this with the NSE as a statutory disclosure, categorised under investor presentation. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by RPG Life Sciences Limited. Read the original for the full detail.